NCT01794793 2024-10-01
Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies
RECORDATI GROUP
Phase 4 Completed
Clinical Trials
13 trialsNCT02419664 2022-03-31
Ga-68-DOTATOC -PET in the Management of Pituitary Tumours
Göteborg University
Phase 3 Terminated
NCT01861717 2021-09-30
A Pilot Study of Pre- and Post-operative Use of Somatuline Depot.
Saint John's Cancer Institute
Phase 4 Terminated
NCT04529356 2020-08-27
The TMS Treatment for Postoperative Headache in GH Tumor
Huashan Hospital
Phase NA Unknown
NCT01673646 2019-09-16
Efficacy and Safety of Pasireotide LAR (Long-acting Release) in Japanese Patients With Acromegaly or Pituitary Gigantism
Novartis
Phase 2 Completed
NCT03439709 2018-03-01
MERGE
Samsung Medical Center
Phase 3 Unknown
NCT02299089 2017-12-15
Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs)
Camurus AB
Phase 2 Completed
NCT00376064 2017-03-06
Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly
Novartis
Phase 4 Completed
NCT00171886 2017-02-24
Octreotide Efficacy and Safety in First-line Acromegalic Patients
Novartis
Phase 4 Completed
NCT00001860 2008-03-04
Sandostatin LAR Depot vs. Surgery for Treating Acromegaly
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00017927 2008-03-04
A Study of the Effects of Pegvisomant on Growth Hormone Excess in McCune-Albright Syndrome
National Institutes of Health Clinical Center (CC)
Phase 3 Completed
NCT00627796 2008-03-03
ATG1line
Federico II University
Phase 4 Completed
NCT00461149 2007-04-17
HDacro
Federico II University
Phase 4 Completed